22 November 2024

Starpharma to present at US Drug Delivery Conference

Melbourne, Australia; 26 October 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

 

The PODD conference is attended by senior licensing and development executives from pharma and biotech with an interest in drug delivery. Speakers include industry experts from companies such as Roche, Biogen, Pfizer, Genentech, AstraZeneca and Sanofi as well as representatives from leading drug delivery companies.

 

In addition to the presentation of the DEP™ platform, Starpharma’s VP Business Development, Dr Tony Eglezos, has been invited to join a panel alongside senior executives from AstraZeneca, Pfizer and Roche. The panel will discuss what makes their alliances successful, including how they were created, lessons learned, and factors contributing to successful partnerships. Dr Eglezos has been asked to reflect on Starpharma’s successful track record in working with Big Pharma with a focus on collaborations based on Starpharma’s DEP™ platform, including Targeted DEP™.

 

Dr Eglezos is presenting Starpharma’s DEPTM drug delivery platform in the Injectable Formulation Technologies session. This presentation highlights the broad applicability of the DEP™ platform and includes data on:

  • DEP™ docetaxel which is currently in the final stage of Phase 1 trial showing an absence of neutropenia and promising efficacy signals;
  • DEPTM cabazitaxel, Starpharma’s dendrimer-enhanced, detergent free version of cancer drug Jevtana®. DEPTM cabazitaxel significantly outperformed Jevtana® in a human breast cancer preclinical model with respect to both level and duration of anticancer activity and survival, and with superior safety; and
  • Starpharma’s novel antibody-targeted DEPTM conjugate, which resulted in complete tumour regression and 100% survival in an ovarian cancer model.

 

At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies.

 

View Presentation: Starpharma presentation at 2016 PODD Conference ( pdf file, 1.7MB) 

Download Announcement: Starpharma to present at US Drug Delivery Conference ( pdf file, 86kb)


This contains certain forward-looking statements.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.